A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells-Reference-Cited by-同舟云学术

A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

Published:2022-02-23 Issue:7900 Volume:603 Page:328-334
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Seung Edward,Xing Zhen,Wu Lan,Rao Ercole,Cortez-Retamozo Virna,Ospina Beatriz,Chen Liqing,Beil Christian,Song Zhili,Zhang Bailin,Levit Mikhail,Deng Gejing,Hebert Andrew,Kirby Patrick,Li Aiqun,Poulton Emma-Jane,Vicente Rita,Garrigou Audrey,Piepenhagen Peter,Ulinski Greg,Sanicola-Nadel Michele,Bangari Dinesh S.^ORCID,Qiu Huawei,Pao Lily^ORCID,Wiederschain Dmitri,Wei Ronnie,Yang Zhi-yong^ORCID,Nabel Gary J.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-022-04439-0.pdf

Reference43 articles.

1. Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).

2. Goebeler, M. E. & Bargou, R. C. T cell-engaging therapies—BiTEs and beyond. Nat. Rev. Clin. Oncol. 17, 418–434 (2020).

3. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).

4. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).

5. Bhoj, V. G. et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood 128, 360–370 (2016).

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Distribution characteristics of immune infiltration and lymphovascular invasion in patients with breast cancer skin recurrence;Cancer Immunology, Immunotherapy;2024-09-05

2. HER2-low gastric cancer: is the subgroup targetable?;ESMO Open;2024-09

3. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies;The Lancet Haematology;2024-09

4. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09

5. Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges;Acta Pharmaceutica Sinica B;2024-09